Home builder Lennar reports boost in fourth-quarter sales
Home builder Lennar Corp. (LEN) on Thursday reported sales that beat expectations in house deliveries and new orders, though the company's stock was down 4% in after-hours trading. The Miami-based company posted fourth-fiscal-quarter earnings of $1.36 billion, or $4.82 a share, compared with $1.32 billion, or $4.55 a share, for the same period a year earlier. Analysts polled by FactSet had forecast earnings per share of $4.59 on revenue of $10.23 billion. Revenue rose 8%, to $10.97 billion. Lennar delivered 23,795 homes in the quarter, up 19% from a year earlier, with new orders rising 32%, to 17,366. Its average sales price did, however, decline to $441,000 from roughly $500,000 last year. Shares of Lennar have soared 71% this year, while the S&P 500 index is up 23%.
-Jon Swartz
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
12-14-23 1713ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track